Thank you, Chair.
I want to start by saying how refreshing it is to be having this conversation in the context of the understanding that Canada, along with the rest of the world, is transitioning to an electric economy. That's the baseline that we're having this discussion on, which, as I said, I find very refreshing.
I want to start on the radioisotope side. I'm a representative of Hamilton West—Ancaster—Dundas. McMaster is in my riding. We have AtomVie and Fusion Pharmaceuticals as those next-generation pharmaceutical companies that are, as you said, Mr. Cameron, located local to the production. They're also doing the processing. Fusion Pharmaceuticals, in particular, was sold to AstraZeneca recently for $2.4 billion.
It's not just the sale of the isotopes or the market for isotopes; the real growth industry that I see is in the processing facilities and the expertise that's needed.
You talked about having production and processing together, but part of the nature of radioisotopes is that they have to be together. How important is it for the growth of those industries to build on both those factors?
